PJSC “HSCI” – The Human Stem Cells Institute (“HSCI”, MOEX: ISKJ), one of Russia’s leading biotech companies, today announced its audited consolidated results for 2017 in accordance with the International Financial Reporting Standards (IFRS).  

Human Stem Cells Institute

Human Stem Cells Institute PJSC (HSCI) is a Russian public biotech company founded in 2003.

HSCI is engaged in drug discovery, R&D and marketing of innovative proprietary products and services in the field of regenerative medicine, bio-insurance, medical genetics, including reproductive genetics, gene therapy and biopharmaceutics.

The Company aims to foster a new culture of medical care – developing new health care opportunities in such areas as personalized and preventive medicine. 

HSCI owns the largest family cord blood stem cell bank in Russia and the CIS – Gemabank®, as well as the reproductive cell and tissue bank Reprobank® (personal storage and donation).

The Company launched Neovasculgen®, the first-in-class gene therapy drug for the treatment of Peripheral Arterial Disease, including Critical Limb Ischemia, and also introduced the innovative cell technology SPRS-therapy®, which entails the use of autologous dermal fibroblasts to repair skin damage due to aging and other structural changes.

HSCI is implementing a socially significant Genetico® project for the development of its own Medical genetics center & lab to provide a wide range of genetic testing and counseling services with the aim of early identification, prediction and prophylactic treatment of genetic disorders, including reproductive system diseases (e.g. PGS/PGDNIPT, Oncogenetics, Bioinformatics, diagnostic panels for specific disease categories and cases).

The Company actively promotes its products on the Russian market and intends to open new markets throughout the world. 

HSCI is listed on the Innovation & Investment Market (iIM) of the Moscow Exchange (ticker ISKJ). The Company conducted its IPO in December 2009, becoming the first Russian biotech company to go public.

Q12017 IFRS FY2016 IFRS